Sygnature Discovery > Diabetes

Diabetes

Sygnature Discovery has broad expertise within the fields of type 2 diabetes and metabolic disease and has successfully delivered compounds to preclinical development for clients in this therapeutic area.

We have an experienced team of multi-disciplinary scientists with a record of delivery in the metabolic disease space. Using their depth of knowledge and RenaSci, a Sygnature Group company; a leading provider of in vivo models specific for studying metabolic disorders, our scientists can offer tailored integrated solutions to support your discovery projects.

Our bioscientists have developed a wide range of relevant assays across a number of assay platforms, including high content imaging, providing our clients with bespoke assays to probe compound mechanism of action studies and tailored screening cascades to support Hit Identification and Lead Optimisation programs. Sygnature’s scientists understand the importance of translational biology and as such offer solutions for the evaluation of both tissue and blood-based biomarkers in PD models of obesity and type 2 diabetes.

Our integrated drug discovery teams provide:

  • A transparent and collaborative work ethic supported by state of the art Informatics to share data.
  • High quality integrated capabilities via our co-located Medicinal, Computational Chemistry and Bioscience.
  • Industry standard in vitro assays for the support of metabolic disorder discovery programs, such as: Glucose-Stimulated Insulin Secretion (GSIS) assays in mouse (Min6, bTC-6) and hamster cell models (HIT-T15), GLP-1 secretion assays in intestinal L cell systems (murine GLUTag cells) and glucose uptake in adipocytes and differentiated 3T3L1 fibroblasts.
  • Tailored assays to probe target engagement and signalling pathways in both recombinant and immortalized cell models.
  • Models of hormone release via functional assays developed in models of pancreatic beta-cells.
  • Intellectual input into project screening strategy and design of relevant and efficient in vitro and ex vivo Screening Cascades.
  • Timely provision of data through our ELN to support client patent applications.
  • Clinical Biomarker Identification and validation.
  • In vivo support via our established network of Strategic Partners.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Opt In *

Oncology and Immuno-oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.

DISCOVER

Diabetes

Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. We have established assays to support the investigation of diabetic therapies including relevant functional assays. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.

DISCOVER

Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.

DISCOVER

Anti-Infectives

Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.

DISCOVER

Neuroscience

Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.

DISCOVER

Respiratory

We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects

DISCOVER

Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.

DISCOVER